Market Overview

I think you’ll love what you hear,
what you’ll see and the opportunities
that will be set before you.
- Jon Najarian

Investment Firm That Held Stake In Valeant Sued By Investors


Shares of Valeant Pharmaceuticals Intl Inc (NYSE: VRX) are lower by 16 percent since the start of 2016 and lower by nearly 45 percent over the past year.

The losses in Valeant Pharmaceuticals' stock has prompted a group of investors to sue an investment firm that saw more than $2 billion in losses from the stock.

According to Reuters, investors who bought into the Sequoia Fund are suing the fund's portfolio managers - Robert Goldfarb and David Poppe, along with two directors for letting the fund amass a stake in Valeant that represented 32 percent of all assets under management in August.

The suit accused the fund managers as being "akin to a gambler at the race track betting more than one quarter of his net worth on a fast horse with a history of maladies and with improbably high odds."

The lawsuit seeks to recoup damages and management fees for the fund.

Posted-In: David Poppe Reuters Robert Goldfarb Sequoia Fund Valeant valeant pharmaceuticalsNews Legal


Related Articles (VRX)

View Comments and Join the Discussion!

MannKind Issues Management Update

Ford CEO Mum On Google Talks At Auto Show